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Abstract
Purpose of Review Patients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events;
therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to
review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for
secondary prevention for CAD.
Recent Findings Intra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary
pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with
high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies
and played a role in improving our understanding of the disease processes.
Summary Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the
impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.
Keywords Coronary artery disease . Coronary atherosclerosis . Vulnerable plaque . Intra-coronary imaging . Secondary
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Introduction
Patients diagnosed with coronary artery disease (CAD) are at a
high risk of subsequent cardiovascular events. Modifications of
risk factors can significantly reduce these recurrent events and
premature death amongst these patients. For that reason, sec-
ondary prevention in the form of therapeutic lifestyle changes,
and drug therapies is vital. The evaluation of treatment effect
and risk stratification during follow-up is important because this
may enable more intensive treatment, motivation and strict
follow-up to reduce clinical outcomes. In addition to clinical
outcomes, a number of tools are used to evaluate the impact of
preventive strategies including biomarkers or imaging modali-
ties. With regard to imaging of coronary atherosclerosis, intra-
vascular modalities are able to provide high-resolution images
that neither angiography nor other non-invasive modalities
could. These techniques have been used in landmark studies
and played a role in improving the understanding of the disease
processes and the prevention strategies. Therefore, this article
aims to review potential application of intra-coronary imaging
(ICI) for the evaluation of plaque modifications induced by
medications for secondary prevention for CAD.
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Why Is Intra-coronary Imaging Important?
ICI for Better Definition of Atherosclerotic Coronary
Disease
Atherosclerotic plaque is the primary pathological substrate
leading to ischemic cardiovascular events, and interventions
that have favourable effects on the atherosclerotic plaque are
expected to improve clinical outcomes [1]. Therefore, athero-
sclerosis imaging can be utilized as an indicator of the ongoing
pathologic process and response to therapeutic interventions.
Coronary angiography has been the gold standard for detect-
ing and guiding the treatment of atherosclerotic coronary ar-
tery disease. However, despite objective and reproducible
measurements can be obtained by quantitative coronary angi-
ography (QCA), it remains limited to merely reflecting the
degree of lumen intrusion of atherosclerotic lesion in the con-
trast filled lumen. Especially in the early stages of the disease,
plaques can show an outward growth, known as positive re-
modelling, without luminal compromise, not detectable by
conventional angiography. Furthermore, the characteristics
and composition of the plaque cannot be adequately studied
by angiography, which only shows large calcifications and
ulcerations. Finally various factors such as diffuse disease,
vessel foreshortening, angulation, overlap, calcification, ec-
centricity and contrast streaming make angiographic assess-
ment challenging [2]. Therefore, ICI modalities have been
developed to overcome these limitations of conventional an-
giography. Moreover, ICI provides detailed evaluation of the
plaques to discriminate between high- and low-risk lesions
and/or patients. From pathological and clinical studies, we
know that plaques at high risk for rupture share certain char-
acteristics [3]. Various ICI modalities can detect these features
associated with high risk and allow serial in vivo imaging of
lesions, contributing to our understanding of the natural his-
tory of plaques and the effect of treatment. In fact, detecting
high-risk features potentially helps in identifying patients in
need of intensive anti-atherosclerotic regimens. The opposite
is also true for the lower risk groups. If we can truly classify
these patients, intensity of the treatments can be softened and
decrease drug-related side effects, and repeated follow-up
visits can be safely avoided allowing us to concentrate on truly
high-risk individuals. Consequently, if we manage to focus
our efforts in the group at higher risk, we may increase
their compliance with regular follow-up visits and predict
new acute events with frequent provocative tests [4].
Finally, atherosclerosis is a systemic disease; thus, focal
therapies are by no means the main therapy. However, in
the presence of an effective focal treatment strategy, to
help reduce the number of patients with high-risk plaques,
ICI may contribute by helping to identify a certain subset
of patients who may benefit from these therapies, along-
side systemic treatments [4].
ICI for Evaluation of Treatment Plaque Modification
ICI provides a close look to the atherosclerotic plaque, which
cannot be substituted by any non-invasive imaging.
Consequently, changes in size and composition over time
can be evaluated in matched arterial segments. These changes
not only help understanding the impact of a treatment but can
also be used as a surrogate clinical end point, which is impor-
tant in testing new drugs [5]. Secondary prevention by means
of vigorous risk modification and consistent use of antiplatelet
and lipid-lowering agents according to guidelines significant-
ly reduces event rates also in the placebo arm of trials testing
new drugs, requiring studies on a larger numbers of patients
over longer periods of time in order to reach a sufficient event
rate to provide a sufficient statistical power and making the
demonstration of an incremental effect of new agents more
challenging [6]. On the other hand, surrogate imaging end
points may allow a smaller group of patients to be studied
for a shorter period of time and accelerate the drug develop-
ment and analysis. This approach may indeed reduce the costs
greatly and potentially prevent the risk of advancing ineffi-
cient therapies before further testing [7–9].
Treatment and Plaque Modifications
Statins
The clinical benefits of statins have consistently been demon-
strated in numerous large-scale studies. They are regarded as
one of the key drugs in the primary and secondary prevention
of CAD [10–12]. Early statin trials employed conventional
angiography to assess their effect on the atherosclerotic
plaque, in an attempt to demonstrate that aggressive lipid-
lowering therapy could halt the progression and even promote
regression of coronary atherosclerosis [13–15]. However, re-
sults of early studies of lipid lowering showed a phenomenon
that was later called “the angiographic paradox”. The im-
provements in lumen measurements were unexpectedly small
and inconsistent when compared with the large reductions in
the clinical event rates [16]. The awareness of the phenome-
non of positive remodelling and the importance of plaque
characteristic and composition explains why angiography
should be replaced by ICI to address directly the plaque
changes.
Several small studies with ICI demonstrated favourable
effects of statins. In one of the earliest studies utilizing
IVUS, Takagi et al. showed that pravastatin reduced progres-
sion of coronary artery atherosclerotic plaque [17]. An
angioscopic study also demonstrated that lipid-lowering ther-
apy by statins dramatically decreased the yellow grade of cor-
onary plaque [18]. Benefits of statins, particularly high-
intensity statin therapy, have been shown in further larger
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studies with ICI. The REVERSAL study comparing prava-
statin 40 mg vs atorvastatin 80 mg for 18 months revealed a
significant increase in IVUS-determined atheroma volume in
pravastatin arm whereas no significant change in intensive
therapy arm [19••]. Subsequently, the ASTEROID study
showed, for the first time, that very intensive cholesterol low-
ering with rosuvastatin can even regress the atheroma burden
(0.79% reduction in atheroma volume detected by IVUS)
[20••]. This effect of intensive statin therapy was further ex-
plored in the SATURN. Despite the lower level of LDL-C and
the higher level of HDL-C achieved with maximal doses of
rosuvastatin compared with atorvastatin, both treatment arms
resulted in significant but comparable regression of coronary
atherosclerosis during 104 weeks of therapy [21••]. Around
about two-thirds of study patients demonstrated a regression
of atherosclerosis and a reduction in the primary efficacy end
point, percent atheroma volume in atorvastatin and
rosuvastatin groups found to be 0.99% and 1.22%, respective-
ly. Both this frequency and level of regression were excep-
tional, as compared with the results of prior IVUS studies
[21••].
Nonetheless, the fact that plaque regression observed in
these studies are only modest (measuring approximately in
1% level) raises the question of how statin therapy is associ-
ated with a significant decrease in cardiovascular events with
such small reductions in plaque burden [1].
A possible explanation could be the potential favourable
changes in plaque composition. The effect of statins on plaque
composition has been firstly investigated using IB-IVUS sys-
tem byKawasaki et al. and showed significant reduction in the
lipid component [22]. In the IBIS-4 study, patients with
STEMI were treated with high-intensity rosuvastatin (40 mg/
day) over a 13-month period. Despite significant atheroma
regression, no change in VH-IVUS defined percent necrotic
core was observed during serial examinations [23•]. Likewise,
in the radiofrequency-IVUS subset of SATURN including 71
patients, a change in necrotic core volume did not accompany
regression of coronary atheroma with maximally intensive
statin therapy [24].
Compositional changes with statins have also been inves-
tigated using near infrared spectroscopy (NIRS). NIRS can
detect and quantify the presence of lipid core in the athero-
sclerotic plaque (Fig. 1), and NIRS-IVUS catheters may asso-
ciate it with other features such as lumen size and plaque
architecture [25]. Furthermore, NIRS imaging of non-
obstructive coronary territories can aid in identifying patients
and segments at higher risk for future events [26].
The YELLOW trial randomized patients with multi-vessel
CAD randomized to a treatment of either rosuvastatin 40 mg
daily or the standard-of-care lipid-lowering therapy. Even af-
ter 6–8 weeks of a short-term intensive statin therapy, a sig-
nificant reduction in the plaque lipid composition was dem-
onstrated with maximum lipid core burden index in 4 mm
(maxLCBI4mm) [27•] (see Fig. 2 for example illustrating
IVUS and NIRS of a patient in the intensive group). In con-
trast, IBIS-3 study failed to demonstrate a significant reduc-
tion of necrotic core volume or LCBI under high-intensity
rosuvastatin therapy for 1 year [28].
Another important change in plaque composition is the
calcification of the atherosclerotic plaque. In a recently pub-
lished study, Puri et al. using IVUS data from a post hoc
patient-level analysis of 8 prospective randomized trials on
serial changes in coronary atheroma showed that statins pro-
mote calcification of the atheroma independently of their
plaque-regressive effects [29]. Authors concluded that such
results highlight the possible procalcific effects of statins,
which may be related to possible plaque-stabilizing effects.
Along with these findings, high-resolution OCT images intro-
duced new possibilities into how statins act to stabilize
plaques (Fig. 3).
In a study on 40 patients with previous myocardial infarc-
tion revealed that the degree of increase of fibrous cap thick-
ness (FCT) was significantly greater in the statin treatment
group than in the control group [30]. Recently, investigators
showed that atorvastatin therapy at 20 mg/day provided a
greater increase in FCT compared with 5 mg, which was as-
sociated with the decrease in serum atherogenic lipoproteins
and inflammatory biomarkers [31]. In the YELLOW II study,
which included 85 stable coronary artery patients, subjects
were given 40 mg of rosuvastatin every day for 8–12 weeks.
Baseline OCT minimal FCT was 100.9 ± 41.7 μm and signif-
icantly increased upon follow-up-FCT (108.6 ± 39.6 μm).
The changes in FCT were also independently associated with
the increase in cholesterol efflux capacity [32•].
PCSK9 Inhibitors
Proprotein convertase subtilisin/kexin type 9 serine protease
(PCSK9) plays a critical role in cholesterol metabolism. By
binding to the LDL receptor and promoting their degradation
and therefore reducing LDL uptake on the hepatocytes,
PCSK9 increases LDL-C levels [33]. Moreover, PCSK9
might contribute to atherosclerosis by mechanisms indepen-
dent of the LDL-C levels [34]. In the ATHEROREMO-IVUS
study, serum PCSK9 levels were linearly associated with the
fraction and amount of IVUS-VH necrotic core tissue [35].
Consequently, monoclonal antibodies against PCSK9 have
emerged as a new and potent class of cholesterol lowering
drugs. Recently, the GLAGOV trial evaluated the effects of
the evolocumab on atherosclerosis with IVUS. Nine hundred
sixty-eight patients with angiographic coronary disease were
randomized to receive either evolocumab or placebo along
with the statins for 18 months. Lower levels of cholesterol in
the evolocumab group (36.6 vs 93.0 mg/dL) was associated
with reduction in percent atheroma volume for evolocumab
(− 0.95% vs + 0.05% in the placebo group) [36••].
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Currently ongoing PACMAN-AMI (NCT03067844) study
will investigate the effect of the PCSK9 inhibitor alirocumab
in a total of 220 acute MI patients undergoing PCI in the
infarct-related artery and receiving guideline-recommended
high-intensity statin therapy. A serial, multi-vessel imaging
study will be performed to determine the change in plaque
Fig. 2 Top panel: On the left, the
baseline angiographic image with
FRR evaluation and the
intravascular ultrasound cross-
sectional images of the plaque are
shown. On the right, the
measurement of lesion lipid core
burden index (LCBI) and LCBI at
the 4-mm maximal segment
(LCBI4mm max) are shown.
Bottom panel: On the left, the
follow-up angiographic image
with FRR re-evaluation and
follow-up intravascular
ultrasound cross-sectional image
are shown. On the right, the
reduction of lesion LCBI and
LCBI4mm max are shown.
(Adapted from: Kini AS et al. J
Am Coll Cardiol. 2013
Jul;62(1):21–9, with permission
from Elsevier) [27]
Fig. 1 Example of correlation between NIRS chemogram and histologic
findings. Vessel tissue lacking necrotic lipid core corresponds to ‘red’ in
chemogram (a and d—fibrous PIT), whereas necrotic lipid core plaques
correspond to ‘yellow’ (b and c—early stage fibroatheromas). Movat’s
pentachrome stain used for histologic evaluation. (Adapted from: Kilic ID
et al. Eur Heart J Cardiovasc Imaging. 2015;16(12):1299–306, by
permission of Oxford University Press) [25]
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volume, lipid parameters byNIRS, andmacrophages and FCT
by OCT at week 52.
Raising HDL
Several epidemiologic studies provided robust evidence that
low levels of high-density lipoprotein cholesterol (HDL-C)
are a significant predictor of CV risk [37, 38]. Greater in-
creases in HDL-C are associated with a significantly reduced
atheroma progression and lower events even in patients using
statins [39]. A pilot study in patients with acute coronary
syndromes investigated the effect of recombinant apolipopro-
tein (apo) A-1 Milano [40], which rapidly mobilized choles-
terol and thereby reduced atherosclerotic plaque burden in
experimental atherosclerosis models [41]. In this study, the
recombinant ApoA-I Milano/phospholipid complex (ETC-
216) administered intravenously for 5 doses at weekly inter-
vals resulted significant regression of coronary atherosclerosis
as measured by IVUS [40]. Further analysis from this study
showed that regression of atherosclerotic plaque was charac-
terized by a concomitant shrinkage of the EEM, which results
in a lumen size that is virtually unchanged [42]. In other
words, large changes in atheroma volume can occur with only
minor luminal changes, which can be undetectable by angiog-
raphy, supporting the importance of ICI.
Another attractive strategy for raising HDL levels is via
inhibiting cholesteryl ester transfer protein (CETP).
Torcetrapib was the first CETP inhibitor evaluated in phase
III clinical trials; however, despite a substantial increase in
HDL-C and decrease in LDL-C, there was no significant de-
crease in the progression of coronary atherosclerosis when
compared with atorvas ta t in monotherapy in the
ILLUSTRATE trial [43]. Moreover, torcetrapib was
discontinued after a large clinical study was terminated pre-
maturely due to increased risk of mortality and morbidity rates
[44]. However, in a post hoc analysis of ILLUSTRATE trial,
the extent of HDL-C increase was found to be inversely relat-
ed to torcetrapib treatment as well as the degree of regression
of atherosclerosis measured by IVUS [45]. Moreover, regres-
sion of atherosclerosis was observed in patients who achieved
the highest levels of HDL-C with torcetrapib, supporting the
notion that the achievement of very high levels of HDL-C via
CETP inhibition has the potential to generate functional HDL
particles that participate in reverse cholesterol transport [45].
In a recently published study, CER-001 infusions, an
engineered lipoprotein particle mimicking pre-beta HDL
and consisting of a combination of recombinant human
apolipoprotein A-I and two phospholipids, also failed to
reduce coronary atherosclerosis on IVUS and QCA when
compared with placebo [46]. Finally, in the ApoA-I
Synthesis Stimulation and Intravascular Ultrasound for
Coronary Atheroma Regression Evaluation (ASSURE) tri-
al, patients with coronary artery disease will be treated
over a period of 26 weeks, and change in percentage of
atheroma volume will be assessed by IVUS compared with
baseline (NCT01067820).
Fig. 3 Coronary and intracoronary images of 47-year-old male patient in
the statin treatment group. Four panels illustrate corresponding images
with similar angle of coronary angiography (a and e) and corresponding
cross-sectional images of IVUS (b and f), and OCT (c, d, g, h) at baseline
and at 9-month follow-up. Fibrous cap thickness at the same cross-
sectional image was increased from 110 (white arrows in D) to 320 m
(white arrows in H) during 9-month follow-up period assessed by OCT.
(Adapted from: Takarada S et al. Atherosclerosis. 2009 Feb; 202(2):491–
7, with permission from Elsevier) [30]
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Lipid Apheresis
LDL-apheresis is an extracorporeal procedure to remove
LDL-C and lipoprotein particles and provides a robust im-
provement in plasma lipoprotein profiles. In a small study in
patients with familial hypercholesterolemia, lipid apheresis in
addition to medical therapy resulted in a significant increase in
minimal lumen diameter by coronary angiogram and decrease
in plaque area by IVUS at 1 year compared with medical
therapy alone, suggesting a possible regression of atheroscle-
rosis by LDL-apheresis [47].
Other Systemic Therapies
Impact of other currently available, such as ezetimibe [48, 49]
or experimental non-statin modifying drugs, such as acyl–
coenzyme A:cholesterol acyltransferase (ACAT), has also
been investigated with IVUS. The enzyme esterifies choles-
terol in a variety of tissues, and inhibition of the ACAT may
prevent excess accumulation of cholesteryl esters in macro-
phages. However, 2 studies failed to show that ACAT inhibi-
tion favourably alters coronary atherosclerosis as assessed by
IVUS [50, 51].
Modification of risk factors other than lipid profile also has
an impact on the atheroma progression. In PERISCOPE trial,
pioglitazone treatment resulted in a significantly lower rate of
progression of coronary atherosclerosis compared with
glimepiride in patients with type 2 diabetes (DM) and coro-
nary artery disease [52]. Moreover, in patients with DM, once
atherosclerosis is established, this is associated with an in-
creased extent, complexity, and a more rapid progression than
seen in non-DM patients. In DM patients, certain characteris-
tics beyond ischemia, such as coronary atherosclerosis bur-
den, progression and plaque composition, may need to be
considered for a more refined risk stratification in these
high-risk patients [53]. Recently, it is reported that DM pa-
tients with angiographically intermediate coronary lesions re-
main at risk for future MACE events, including those patients
with FFR negative lesions [54]. Thus, combining functional
assessment with imaging techniques may be required to guide
our treatment strategy in these patients with high-risk, fast-
progressing atherosclerosis. The COMBINE (OCT-FFR)
(NCT02989740) is enrolling patients to examine whether the
addition of OCT plaque morphological evaluation to FFR
hemodynamic assessment of intermediate lesions in DM pa-
tients will better predict MACEs and possibly lead to new
therapeutic strategies [55].
In the CAMELOT trial which assessed 2 different drug
regimens vs placebo in patients with CAD patients, IVUS
showed progression in the placebo group, a trend toward pro-
gression in the enalapril group, and no progression in the
amlodipine group [56]. In the STRADIVARIUS trial, after
18 months of treatment, the weight loss drug rimonabant has
failed to show an effect on disease progression for the primary
end point percent atheroma volume but showed a favourable
effect on total atheroma volume, the secondary end point [57].
The effects of a selective oral inhibitor of lipoprotein-
associated phospholipase A2, darapladib, were compared with
of placebo in patients with CAD. This enzyme is expressed
abundantly in the necrotic core and may contribute plaque
vulnerability [58]. After 12 months, there were no significant
differences between groups in plaque deformability with
IVUS palpography or plasma high-sensitivity C-reactive pro-
tein. In the placebo-treated group, however, necrotic core vol-
ume increased significantly, whereas darapladib was found to
halt this increase, without a significant difference in total ath-
eroma volume [58]. Nonetheless, further clinical trials failed
to show a reduction in events in both stable [59] and acute
CAD [60].
Local Interventional Therapies
One of the potential treatment approaches under investigation
for the high-risk plaques is the local treatment to sealing by the
neo-intima formation which resembles a thick-cap and/or pas-
sivating the plaque by local immunomodulation. In this re-
gard, ICI is not capable of detecting these “hot spots”, which
carry a high risk, but additionally reveals any changes in vul-
nerable plaque characteristics with these treatments. A small
pilot study tested the vShield self-expanding nitinol device
(Prescient Medical, Inc., Doylestown, PA, USA), in which
high-risk plaques were detected by VH-IVUS and OCT (see
Fig. 4). The average baseline FCT, measured by OCT, was 48
± 12 μm and increased to 201 ± 168 μm with neo-cap forma-
tion in the 6 months follow-up, which might contribute to
stability of the plaque [61]. Similarly, using OCT, Brugaletta
et al. showed the formation of a neointima layer after the
implantation of a bioresorbable vascular scaffold that resem-
bles a thick fibrous cap, which may contribute to stabilization
of the plaque [62]. Although the concept is promising, it re-
quires further investigation.
Limitations
There are also limitations to the utilization of ICI for the stud-
ies. To start with, studies using ICI for surrogate end points
needs to be interpreted with caution. This is because regard-
less of how promising a surrogate end point seems, the true
clinical benefit may remain uncertain [63]. Also, there is al-
ways a possibility for unexpected off-target effects which may
counterbalance the favourable effects. As mentioned previ-
ously, there are a number of examples where imaging markers
showed benefit; however, subsequent clinical trials failed to
show a clinical benefit or even showed harm.
Moreover, alterations with therapies do not always signify
a clear-cut relation and/or causation. For instance, as
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previously mentioned, the reported effects of statins on plaque
regression are modest, indicating that despite the statistical
significance of this drug therapy, improvements in clinical
outcomes may not be directly related to these minute changes
in the vessel wall—so the mechanisms of the favourable ef-
fects of statins remained speculative.
Furthermore, despite the safety of these modalities are well
documented [64, 65], they are not completely free of compli-
cations, and especially repeated examinations may be of con-
cern with the use of ionizing radiation, contrast media and a
need a vascular access.
Moreover, each individual modality provides information
on different aspects of the lesion morphology and composi-
tion, complementing each other and otherwise lack perfection
on their own. Additionally, a major limitation is the inability
to assess specific biological processes with the currently avail-
able techniques. Molecular imaging techniques are also under
development, with an aim to image-specific molecules and
cells involved in the pathogenesis of disease using specialized,
targeted imaging agents that bind to specific molecular or
internalized within a cell [66–68]. In the future, these
techniques may potentially allow the functional evaluation
of the effect of therapeutic interventions on lesion activity.
There are also technical considerations on the use of ICI.
First, acquiring good-quality images is not always possible;
moreover, there are a number of artefacts which can preclude
accurate measurements [7]. Secondly, matching the arterial seg-
ments can sometimes be challenging in different time points,
although current co-registration systems may improve the cor-
relations of different techniques. Another limitation is the need
for predilatation to cross tight stenoses with the imaging cathe-
ter, which can significantly modify the lesion morphology and
structure. This also hinders evaluation of totally occluded seg-
ments. Similarly, despite it is possible to evaluate the most of
the epicardial coronary arteries, catheter-based imaging does
not allow the visualization of the entire coronary bed [69].
Conclusions
ICI provides detailed information on the atherosclerotic
plaque, which is the primary pathological substrate for the
Fig. 4 a In the upper left,
palpogram showing stain value of
1.4% (Rotterdam Classification
III-IV). b In the upper right,
corresponding matched thin cap
fibroatheroma on IVUS virtual
histology analysis with plaque
burden of 56% and necrotic core
of 34% in three consecutive
frames. c In the lower left corner,
matched OCT frame showing cap
thickness of 40 μm. (Adapted
with permission of Europa Group




Clearance Center, Inc.) [61]
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recurrent ischemic cardiovascular events. These modalities
have been showed to help investigating the effect of the med-
ications for secondary prevention on the atherosclerotic
plaque. Continuous advances in ICI may overcome current
limitations and increase utilization of these modalities in the
trials or even in risk stratification.
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